246 related articles for article (PubMed ID: 3068792)
1. Prognosis of transitional cell bladder carcinoma. With special reference to ABH blood group isoantigen expression and DNA analysis.
Malmström PU
Scand J Urol Nephrol Suppl; 1988; 112():1-55. PubMed ID: 3068792
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of overexpression of p53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy.
Nakopoulou L; Constantinides C; Papandropoulos J; Theodoropoulos G; Tzonou A; Giannopoulos A; Zervas A; Dimopoulos C
Urology; 1995 Sep; 46(3):334-40. PubMed ID: 7660508
[TBL] [Abstract][Full Text] [Related]
3. [The study of the ABH isoantigen of bladder tumors].
Fukatsu H; Nonomura H; Miyagawa Y; Waki M; Hatano Y; Hiraiwa S; Muramatsu T; Takamura T; Yamada Y; Nishikawa E
Hinyokika Kiyo; 1987 Jun; 33(6):857-63. PubMed ID: 3314420
[TBL] [Abstract][Full Text] [Related]
4. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors for primary superficial transitional cell carcinoma of the bladder: a retrospective cohort study.
Yang TB; Zeng FH; Sun ZQ
Chin Med J (Engl); 2006 Nov; 119(21):1821-8. PubMed ID: 17097038
[TBL] [Abstract][Full Text] [Related]
6. Surgically treated transitional cell carcinomas of the bladder. The role of radical surgery.
Al-Ali MA; Kashmoula DM; Haddad LF
Saudi Med J; 2002 Jun; 23(6):695-9. PubMed ID: 12070550
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up.
Cai T; Margallo E; Nesi G; Giubilei G; Rizzo M; Bartoletti R
Oncol Rep; 2006 Jan; 15(1):213-9. PubMed ID: 16328058
[TBL] [Abstract][Full Text] [Related]
8. The value of DNA cytometry in transitional cell carcinoma of the urinary bladder.
Nenning H; Rassler J; Minh DH; Stolzenburg JU
Gen Diagn Pathol; 1997 Dec; 143(4):231-6. PubMed ID: 9489956
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of 300 patients with bladder cancer].
Mori Y; Arima M; Shimada K; Shima H; Ihara H; Yabumoto H; Hosokawa S; Taguchi K; Ikoma F
Hinyokika Kiyo; 1991 Oct; 37(10):1235-41. PubMed ID: 1755417
[TBL] [Abstract][Full Text] [Related]
10. Superficial transitional cell carcinoma of the ureteral orifice: higher risk of developing subsequent upper urinary tract tumors.
Chou EC; Lin AT; Chen KK; Chang LS
Int J Urol; 2006 Jun; 13(6):682-5. PubMed ID: 16834642
[TBL] [Abstract][Full Text] [Related]
11. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
[TBL] [Abstract][Full Text] [Related]
12. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy.
Yu RJ; Stein JP; Cai J; Miranda G; Groshen S; Skinner DG
J Urol; 2006 Aug; 176(2):493-8; discussion 498-9. PubMed ID: 16813876
[TBL] [Abstract][Full Text] [Related]
13. Clinical cancer progression in urinary bladder tumors evaluated by multiparameter flow cytometry with monoclonal antibodies. Laval University Urology Group.
Fradet Y; Tardif M; Bourget L; Robert J
Cancer Res; 1990 Jan; 50(2):432-7. PubMed ID: 2295082
[TBL] [Abstract][Full Text] [Related]
14. Deoxyribonucleic acid ploidy and the clinical pattern of grade 2 superficial bladder cancer.
Neulander E; Kaneti J; Chaimovitz C; Sion-Vardy N; Douvdevani A
J Urol; 1997 Apr; 157(4):1254-8; discussion 1258-9. PubMed ID: 9120914
[TBL] [Abstract][Full Text] [Related]
15. [The study of ABH isoantigen and T (Thomsen-Friedenreich) antigen of superficial urothelial tumor].
Sasaki K
Hokkaido Igaku Zasshi; 1984 Nov; 59(6):679-89. PubMed ID: 6530208
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder.
Durkan GC; Nutt JE; Rajjayabun PH; Neal DE; Lunec J; Mellon JK
Clin Cancer Res; 2001 Nov; 7(11):3450-6. PubMed ID: 11705862
[TBL] [Abstract][Full Text] [Related]
18. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.
Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P
J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma.
Cai T; Nesi G; Boddi V; Mazzoli S; Dal Canto M; Bartoletti R
Oncol Rep; 2006 Aug; 16(2):329-34. PubMed ID: 16820911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]